Aphasia

Current Location

112 Aphasia Trials Near You

Power is an online platform that helps thousands of Aphasia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Cued Picture-Naming Therapy for Aphasia

Columbus, Ohio
Aphasia, or language impairment after a stroke, affects approximately 2 million people in the United States, with an estimated 180,000 new cases each year. The medical community cannot predict how well someone with aphasia will respond to treatment, as some people with aphasia are poor responders to intervention even when participating in empirically supported treatments. There is a strong likelihood that genetics play a role in language recovery after stroke, but very little research has been dedicated to investigating this link. This study will investigate whether two genes and cognitive abilities, such as memory, predict responsiveness to aphasia therapy for word-retrieval difficulties.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

120 Participants Needed

Gene Therapy for Frontotemporal Dementia

Columbus, Ohio
The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement. These symptoms result from below normal levels of a protein called progranulin (PGRN) in the brain, which leads to the death of nerve cells (neurons), affecting the brain's ability to function. The main questions that the study aims to answer are: 1. Is a one-time treatment with AVB-101 safe for patients with FTD-GRN? 2. Does a one-time treatment with AVB-101 restore PGRN levels to at least normal levels? 3. Could AVB-101 work as a treatment to slow down or stop progression of FTD-GRN? In this study there is no placebo (a dummy pill or treatment used for comparison purposes), so all participants will receive a one-time treatment of AVB-101 delivered directly to the brain, with follow-up assessments for 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:30 - 75

9 Participants Needed

AL001 for Frontotemporal Dementia

Cincinnati, Ohio
This trial is testing AL001, a drug given through an IV, to see if it can help people with a genetic mutation that causes frontotemporal dementia. The goal is to find out if AL001 can improve brain health in these individuals.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:25 - 85

110 Participants Needed

Trappsol Cyclo for Niemann-Pick Disease

Cincinnati, Ohio
This trial is testing a medicine called Trappsol Cyclo, given through an IV, for patients with Niemann Pick disease type C1. The medicine helps remove harmful fat buildup in cells. The study will also look at safety in younger children. Trappsol Cyclo has shown promising results by mobilizing cholesterol, extending life, and reducing neurological damage in Niemann-Pick disease type C1.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3+

94 Participants Needed

Adaptive Naming Treatment Schedules for Aphasia

Pittsburgh, Pennsylvania
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using these naming abilities in daily life. The current research aims to evaluate novel anomia treatment approaches to improve long-term retention and generalization to everyday life. This study is one of two that are part of a larger grant. This record is for sub-study 2, which will evaluate the benefits of adaptive trial spacing.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

32 Participants Needed

Learning Strategies for Naming in Aphasia

Pittsburgh, Pennsylvania
Aphasia is a language disorder caused by stroke and other acquired brain injuries that affects over two million people in the United States and which interferes with life participation and quality of life. Anomia (i.e., word- finding difficulty) is a primary frustration for people with aphasia. Picture-based naming treatments for anomia are widely used in aphasia rehabilitation, but current treatment approaches do not address the long-term retention of naming abilities and do not focus on using these naming abilities in daily life. The current research aims to evaluate novel anomia treatment approaches to improve long-term retention and generalization to everyday life. This study is one of two that are part of a larger grant. This record is for sub-study 1, which will adaptively balance effort and accuracy using speeded naming deadlines.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

30 Participants Needed

Speech Sequencing Therapies for Stuttering

Ann Arbor, Michigan
Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is to improve understanding of the brain mechanisms involved in speech motor planning and how these are disrupted in neurogenic speech disorders, like stuttering. The investigators will do this through an integrated combination of experiments that involve speech production, functional MRI, and non-invasive brain stimulation. The study is designed to test hypotheses regarding the brain processes involved in learning and initiating new speech sound sequences and how those processes compare in persons with persistent developmental stuttering and those with typical speech development. These processes will be studied in both adults and children. Additionally, these processes will be investigated in patients with neurodegenerative speech disorders (primary progressive aphasia) to further inform the investigators understanding of the neural mechanisms that support speech motor sequence learning. Together these experiments will result in an improved account of the brain mechanisms underlying speech production in fluent speakers and individuals who stutter, thereby paving the way for the development of new therapies and technologies for addressing this disorder.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:6+

2 Participants Needed

Semantic Feature Analysis Treatment for Aphasia

Pittsburgh, Pennsylvania
This randomized controlled comparative effectiveness study examines manipulation of a key component of an established and efficacious treatment for naming impairments in aphasia, along with cognitive and brain correlates of treatment success. Study participants will be randomly assigned to one of two treatment conditions comparing two different versions of Semantic Feature Analysis treatment. Their performance on standardized and study-specific measures will be used to determine which version of the treatment provides superior outcomes, and measures of automatic language processing and functional brain imaging will also be used to identify the underlying neurocognitive mechanisms associated with positive treatment response.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

40 Participants Needed

Sentence Training for Aphasia

West Lafayette, Indiana
This trial aims to improve sentence production and comprehension in people with aphasia using a technique that subtly influences the brain to enhance language skills without the person being fully aware of it. The goal is to create lasting improvements in language abilities by frequently exposing the brain to certain language patterns.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 85

104 Participants Needed

Nabilone for Frontotemporal Dementia

London, Ontario
The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

45 Participants Needed

AL001 for Frontotemporal Dementia

London, Ontario
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

40 Participants Needed

Oxytocin Nasal Spray for Frontotemporal Dementia

London, Ontario
The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:30 - 80

112 Participants Needed

(18F)-FEPPA PET/MRI Imaging for Frontotemporal Dementia

London, Ontario
Neuroinflammation is increasingly implicated as a potential critical pathogenic mechanism in a variety of neurologic and psychiatric disorders. This study will use hybrid PET/MRI imaging to evaluate neuroinflammation and its relationship to cerebral perfusion in frontotemporal dementia (FTD). Patients with FTD will be recruited from the Cognitive Neurology and Aging Brain clinics at Parkwood Institute and will undergo neurocognitive assessment and MRI/PET using the PET ligand FEPPA which binds to activated microglia, a marker of neuroinflammation. Correlations will be conducted to determine whether abnormal neuroinflammation is present in Frontotemporal dementia and whether differential patterns of neuroinflammation are present in different FTD clinical and molecular subtypes, and to determine the relationship between neuroinflammation, cerebral perfusion using arterial spin labeling MRI imaging techniques, and indices of brain structure including volumetric and white matter analysis.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30 - 95

40 Participants Needed

Script Training for Aphasia

Chicago, Illinois
The purpose of this study is to evaluate how changing conditions of speech-language treatment (namely, amount of repetition and distribution of practice schedule) affects the language outcome of participants with aphasia following a stroke. Using a computer based speech and language therapy program, participants will practice conversational scripts that are either short or long. Participants will practice for either 2 weeks (5 days a week) or for 5 weeks (2 days a week).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+

95 Participants Needed

Speech-Language Therapy for Primary Progressive Aphasia

Chicago, Illinois
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

200 Participants Needed

Communication Bridge for Primary Progressive Aphasia

Chicago, Illinois
The aim of this study is to evaluate the effectiveness and feasibility of evidence-based interventions in individuals living with mild to moderate primary progressive aphasia (PPA) that address communication-focused outcomes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

12 Participants Needed

Verdiperstat for Frontotemporal Dementia

Chicago, Illinois
This trial tests the safety of Verdiperstat, a medication taken regularly, in patients with language difficulties caused by brain issues. The study aims to see if the drug can change protein levels in the brain and improve cognitive functions.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

64 Participants Needed

Tau PET Imaging for Primary Progressive Aphasia

Chicago, Illinois
This trial aims to see if a PET scan with a special tracer can map harmful protein build-up in the brains of people with language problems due to Primary Progressive Aphasia.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:20 - 100

70 Participants Needed

Anomia Treatment for Aphasia

Buffalo, New York
The goal of this clinical trial is to identify predictors of response to phonological-focused anomia treatment in people with aphasia. The main question it aims to answer is who responds to which type of anomia treatment. Researchers will compare Phonomotor Treatment and Phonological Components Analysis to see which treatment is more beneficial, and for whom. Participants will engage in both treatments over several months.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

2 Participants Needed

Choir Singing for Aphasia

Toronto, Ontario
The goal of this randomized controled trial is to test the effects of assigning people with chronic post-stroke aphasia to 12 weekly choir sessions, compared to usual care. The main question it aims to answer is: Does the assignment to a choir singing program causes a beneficial effect on functional communication and language recovery as well as psychosocial outcomes compared to usual care in the rehabilitation of people with chronic post-stroke aphasia? Participants will have: 12 in-person choir-singing sessions (1 session/week, 1,5 h/session, total 18h) conducted by a choir master, and home singing training (3 x 30-minutes-sessions/week, total 18h)
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

50 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Gene Therapy for Frontotemporal Dementia

Toronto, Ontario
This trial tests PBFT02, a gene therapy that uses a virus to deliver a healthy GRN gene to the brain. It targets patients aged 35-75 with frontotemporal dementia caused by GRN mutations. The virus helps bring the healthy gene to brain cells, which may improve their condition. This approach has been proposed as a treatment for this type of dementia.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:35 - 75

25 Participants Needed

Deep Brain Stimulation for Frontotemporal Dementia

Toronto, Ontario
This trial is testing a brain implant that sends electrical signals to help people with a specific type of dementia that causes severe symptoms like apathy. The goal is to see if this treatment can improve their brain function and reduce symptoms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:40 - 85

6 Participants Needed

tDCS + Language Therapy for Primary Progressive Aphasia

Toronto, Ontario
While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80

180 Participants Needed

TDCS + Phonomotor Therapy for Aphasia

Milwaukee, Wisconsin
This study is designed for individuals with aphasia, a language disorder that affects many stroke survivors, making it difficult to read, speak, and understand language. Up to 70% of people with aphasia struggle with reading, which impacts their ability to communicate, work, and engage in daily life. The study aims to test a new approach to reading rehabilitation by combining Phono-Motor Treatment (PMT), a language therapy adapted to improve reading, with transcranial direct current stimulation (tDCS), a safe and painless brain stimulation technique. tDCS delivers a mild electrical current to the brain, which may enhance learning. This study will assess whether adding tDCS to PMT improves reading therapy outcomes.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

50 Participants Needed

Brain Stimulation + Language Therapy for Aphasia

Milwaukee, Wisconsin
The investigator proposes to examine the effects of excitatory transcranial magnetic stimulation (TMS) combined with semantic feature analysis (SFA) language therapy to improve word-finding abilities in stroke survivors with aphasia (SWA).

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

50 Participants Needed

tACS for Aphasia After Stroke

Milwaukee, Wisconsin
This study will assess the effects of transcranial alternating current stimulation (tACS) on language recovery after stroke.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

120 Participants Needed

HD-tDCS + Speech Therapy for Aphasia

Milwaukee, Wisconsin
This study will investigate the effects of mild electrical stimulation in conjunction with speech therapy for people with post-stroke aphasia to enhance language recovery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

200 Participants Needed

TMS for Aphasia

Milwaukee, Wisconsin
This study will examine the effect of TMS on people with stroke and aphasia as well as healthy individuals.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

135 Participants Needed

tDCS + Speech Therapy for Aphasia

Milwaukee, Wisconsin
This study will investigate the effects of mild electrical stimulation in conjunction with speech therapy for people with post-stroke aphasia to enhance language recovery.
No Placebo Group

Trial Details

Trial Status:Recruiting

4 Participants Needed

tACS for Aphasia After Stroke

Milwaukee, Wisconsin
This study is evaluating whether a type of electrical stimulation may help improve language recovery for individuals who have had a stroke.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

50 Participants Needed

1234

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Aphasia clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Aphasia clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Aphasia trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Aphasia is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Aphasia medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Aphasia clinical trials?

Most recently, we added Language Model Assistance for Hospitalized Patients, Aphasia Identification Cards for Aphasia and Brain Stimulation for Traumatic Brain Injury to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Primary Progressive Aphasia Clinical Trials

59 Alzheimer's Disease Trials near Chicago, IL

154 Depression Trials near New York, NY

Top Testicular Cancer Clinical Trials

Top Pancreas Cancer Clinical Trials

Top Gastroenterology Clinical Trials

Top Appendicitis Clinical Trials

Top Glioma Clinical Trials

Top Chondrosarcoma Clinical Trials

Top Perimenopause Clinical Trials

Top Gout Clinical Trials

Top Dysphagia Clinical Trials

By Trial

Speech Therapy for Aphasia

Support Group Program for Progressive Aphasia

tDCS + Language Therapy for Primary Progressive Aphasia

Adaptive Naming Treatment Schedules for Aphasia

Speech-Language Therapy for Primary Progressive Aphasia

VR Speech-Language Therapy for Speech Disorders

Group Psychotherapy for Mild Cognitive Impairment

Strategy Training for Hemispatial Neglect

Brain Stimulation for Dyslexia

Brain Stimulation for Working Memory Issues

Group Singing for Stroke Patients

Brain Stimulation for Speech Improvement

Related Searches

Top Treatment for Lenalidomide Clinical Trials

Top Ovarian-cancer Clinical Trials

Top Treatment for Psilocybin Clinical Trials

Speech-Language Teletherapy for Hearing Loss

Mobile Health Program for High Blood Pressure

Low-Dose Dexmedetomidine for Postoperative Pain in Scoliosis

Durvalumab +/- Tremelimumab for Prostate Cancer

Enasidenib for T-Cell Lymphoma

Preconditioning with Tefillin for Heart Disease

Music Therapy for Pancreatic Surgery

HomeStyles-2 Program for Childhood Obesity

Implantable Brain-Computer Interface for Paralysis

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial